S&P Futures
4,461.50 -13.25 (-0.30%) Dow Futures
34,628.00 +12.00 (+0.03%) Nasdaq Futures
14,726.00 -115.00 (-0.77%) Russell 2000 Futures
2,023.80 +2.60 (+0.13%) Crude Oil
86.29 -0.61 (-0.70%) Gold
1,842.80 +0.20 (+0.01%)
Aura Biosciences, Inc. (AURA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 19.50 |
| Open | 19.99 |
| Bid | 17.83 x 900 |
| Ask | 19.87 x 800 |
| Day's Range | 17.78 - 19.99 |
| 52 Week Range | 13.50 - 26.16 |
| Volume | |
| Avg. Volume | 150,912 |
| Market Cap | 530.463M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -97.02 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.67 |
Fair Value
Related Research
- Aura Biosciences, Inc.Daily – Vickers Top Buyers & Sellers for 01/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 days agoArgus Research
- Business Wire
Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
CAMBRIDGE, Mass., November 24, 2021--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced financial results for the third quarter ended September 30, 2021.
- Business Wire
Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., November 23, 2021--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced that Elisabet de los Pinos, Chief Executive Officer of Aura, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx conference taking place on Tuesday, November 30, 2021 at 2:15 p.m. Eastern Time.
- Business Wire
Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting
CAMBRIDGE, Mass., November 15, 2021--Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of data evaluating its first VDC, AU-011, in indeterminate lesions (ILs) and choroidal melanoma (CM), including final safety and efficacy data from the Phase 1b/2 trial using intravitreal (IVT) administration, as well as updated safety results from the Phase 2 trial using
